Literature DB >> 3056482

Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy.

S S Davis1, N Washington, G D Parr, A H Short, V A John, P Lloyd, S M Walker.   

Abstract

1. The position in the gastrointestinal tract of an orally administered oxprenolol Oros drug delivery system labelled with technetium-99m DTPA was followed by gamma scintigraphy, and the corresponding plasma drug concentration-time profiles after oral and i.v. administration were used to relate pharmacokinetic and transit data. 2. Gastric emptying time (0.8 +/- 0.4 h, mean +/- s.d.), and the time to arrival in the colon (3.8 +/- 0.7 h) were reasonably consistent after administration of the Oros system to fasted subjects, as were the calculated small intestine transit times (3.0 +/- 0.7 h). As expected there were wide individual variations in colonic transit, so that recorded values for total transit ranged from 6 to 32 h (median, 24.7 h). 3. Absorption of oxprenolol occurred throughout the GI tract including the colon. Plasma drug concentration-time profiles and input functions (calculated by deconvolution) could be related to transit behaviour and in vitro release. Inflexions in the calculated rate of drug input when the Oros system was located in the colon corresponded with periods of stagnation at the hepatic and splenic flexures in two subjects and the ileocaecal junction in two others. The mechanism of these changes is unclear.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056482      PMCID: PMC1386566          DOI: 10.1111/j.1365-2125.1988.tb03403.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

2.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

3.  A migrating electric complex of canine small intestine.

Authors:  J H Szurszewski
Journal:  Am J Physiol       Date:  1969-12

Review 4.  The physiology and pathophysiology of gastric emptying in humans.

Authors:  H Minami; R W McCallum
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

5.  Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations.

Authors:  V A John; S E Smith
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

6.  In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations.

Authors:  F Langenbucher; J Mysicka
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report.

Authors:  V A John; P A Shotton; J Moppert; W Theobald
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

9.  Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing.

Authors:  K H Antonin; P Bieck; M Scheurlen; M Jedrychowski; H Malchow
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 10.  Oxprenolol hydrochloride: pharmacology, pharmacokinetics, adverse effects and clinical efficacy.

Authors:  M E Russo; J O Covinsky
Journal:  Pharmacotherapy       Date:  1983 Mar-Apr       Impact factor: 4.705

View more
  11 in total

Review 1.  Gamma scintigraphy in the evaluation of pharmaceutical dosage forms.

Authors:  S S Davis; J G Hardy; S P Newman; I R Wilding
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  Factors influencing the bioavailability of peroral formulations of drugs for dogs.

Authors:  S Sabnis
Journal:  Vet Res Commun       Date:  1999-11       Impact factor: 2.459

Review 3.  Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.

Authors:  James C Ermer; Ben A Adeyi; Michael L Pucci
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

4.  Prediction of intestinal drug absorption properties by three-dimensional solubility parameters.

Authors:  J Breitkreutz
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

5.  Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets.

Authors:  B Abrahamsson; M Alpsten; M Hugosson; U E Jonsson; M Sundgren; A Svenheden; J Tölli
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

6.  Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers.

Authors:  I R Wilding; S S Davis; J G Hardy; C S Robertson; V A John; M L Powell; M Leal; P Lloyd; S M Walker
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

Review 7.  Pharmacokinetic considerations in gastrointestinal motor disorders.

Authors:  G S Hebbard; W M Sun; F Bochner; M Horowitz
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 8.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

9.  In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy.

Authors:  I R Wilding; J G Hardy; R A Sparrow; S S Davis; P B Daly; J R English
Journal:  Pharm Res       Date:  1992-11       Impact factor: 4.200

10.  Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations.

Authors:  J Richard; J M Cardot; J Godbillon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Oct-Dec       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.